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Abstract
Background: Natural Killer (NK) cells are thought to protect from residual leukemic cells in patients receiving stem cell
transplantation. However, multiple retrospective analyses of patient data have yielded conflicting conclusions regarding a
putative role of NK cells and the essential NK cell recognition events mediating a protective effect against leukemia. Further,
a NK cell mediated protective effect against primary leukemia in vivo has not been shown directly.
Methodology/Principal Findings: Here we addressed whether NK cells have the potential to control chronic myeloid
leukemia (CML) arising based on the transplantation of BCR-ABL1 oncogene expressing primary bone marrow precursor
cells into lethally irradiated recipient mice. These analyses identified missing-self recognition as the only NK cell-mediated
recognition strategy, which is able to significantly protect from the development of CML disease in vivo.
Conclusion: Our data provide a proof of principle that NK cells can control primary leukemic cells in vivo. Since the presence
of NK cells reduced the abundance of leukemia propagating cancer stem cells, the data raise the possibility that NK cell
recognition has the potential to cure CML, which may be difficult using small molecule BCR-ABL1 inhibitors. Finally, our
findings validate approaches to treat leukemia using antibody-based blockade of self-specific inhibitory MHC class I
receptors.
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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder characterized by a reciprocal translocation between
chromosome 9 and 22, the so-called Philadelphia (Ph) chromo-
some. This translocation juxtaposes the genes encoding the ABL1
tyrosine kinase and BCR (Breakpoint cluster region), resulting in a
BCR-ABL1 fusion protein with constitutive tyrosine kinase
activity. This activity is critically involved in the initial chronic
phase of CML disease and the subsequent disease progression.
Indeed, the BCR-ABL1 inhibitor imatinib has become the
standard therapy in newly diagnosed CML patients. Based on
multiple clinical studies, a majority of patients (52–69%) achieve a
complete cytogenic response (i.e. no Ph+ metaphases in 20/20
cells) but only a minority of patients (12–40%) achieve a major
molecular response (i.e. a 3-log reduction in BCR-ABL1 mRNA)
by 12 months of treatment [1]. Nilotinib and desatinib are second-
generation inhibitors that exhibit considerably higher activity
against BCR-ABL1 and that show further increased response rates
[1]. Despite the impressive ability to control disease, there are
CML patients that do not respond to BCR-ABL1 inhibitors or in
which the disease progresses, some times based on mutations in
BCR-ABL1. Finally, recurrence has been observed in a significant
fraction of patients when BCR-ABL1 inhibitor treatment is
discontinued [2], suggesting that leukemia initiating cells may
persist and be refractory to inhibitor treatment. Thus additional
treatment options, which are able to target leukemia-propagating
cells, are needed to treat certain CML patients.
Haematopoietic stem cell transplantation has the potential to
cure CML [3]. This is in part due to immune cells present in the
graft and/or developing from grafted stem cells, which mediate a
graft versus leukemia (GvL) effect to eliminate residual leukemic
cells. Unrelated HLA-matched and partially HLA-mismatched
transplants may contain T cells, which recognize minor histocom-
patibility antigens or HLA molecules on residual leukemic cells,
respectively. However, such T cell recognition bears the significant
risk of graft versus host disease (GvHD), a life threatening
complication of (partially) HLA mismatched stem cell transplan-
tation, in which donor-derived T cells attack non-haematopoietic,
healthy tissues of the recipient. A partial HLA mismatch can also
be recognized by NK cells and it has been suggested that
alloreactive NK cells can prevent leukemia relapse following stem
cell transplantation [4]. In contrast to T cells, NK cells do not
seem to cause GvHD [5,6].
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NK cells can react to allogeneic cells based on various
recognition events. First some NK cells can be activated using
receptors, which are specific for allogeneic MHC-I [7,8]. In
addition, many NK cells express inhibitory receptors specific for
MHC-I [9,10]. MHC-I receptors counteract NK cell activation by
receptors specific for ligands that are constitutively expressed on
healthy host cells. This dual receptor system allows the killing of
diseased host cells, which display aberrantly low levels of MHC-I
molecules (missing-self recognition) [11]. Since inhibitory MHC-I
receptors (KIR (Killer Immunoglobulin-like Receptors) in human
and Ly49 family receptors in mice) do not recognize all MHC-I
alleles, the dual receptor system can confer reactivity to allogeneic
cells that express the wrong MHC-I (KIR ligand mismatch). NK
cell alloreactivity is further dependent on NK cell education [12]
i.e. activation receptors on NK cells, which express a KIR/Ly49
specific for self-MHC-I respond more efficiently to stimulation
[13,14,15,16]. Consequently, NK cell alloreactivity depends on
the expression of a KIR/Ly49 and its MHC-I ligand in the donor
(for education) and the absence of MHC-I ligand in the recipient
(for the relieve from inhibition). Conversely, the activation
receptors on NK cells that do not express a KIR/Ly49 specific
for self-MHC-I respond poorly stimulation [13,14,15,16]. How-
ever, the function of these activation receptors can improve when
these uneducated NK cells are exposed to inflammatory cytokines
[14,17]. Consequently, it is possible that uneducated NK cells
acquire reactivity due to the peculiar inflammatory environment
during stem cell transplantation [18]. In addition to NK cell
alloreactivity, there is evidence that the upregulation of stress
induced self ligands, such as those engaging the NKG2D
activation receptor [19], represents an important NK cell
recognition strategy for transformed cells [20]. The importance
of this pathway in the context of GvL is not known.
A role of NK cells to protect from leukemia has been inferred
from the retrospective analysis of data from patients receiving
unrelated HLA matched or partially HLA mismatched hemato-
poietic stem cell transplantation. A reduced relapse and improved
disease free survival of leukemia patients receiving partially
mismatched transplants has been attributed to NK cell allor-
eactivity mediated by the absence of KIR ligand in the recipient
(KIR-ligand mismatch i.e. missing-self recognition) [4]. However,
certain studies have either found no beneficial effect of KIR ligand
mismatch or reported even worse outcomes following partially
HLA mismatched stem cell transplantation [21,22]. Moreover,
other studies have proposed protective roles for NK cell
recognition of allogenic HLA using activating KIR [23,24] or
they suggested a role for uneducated NK cells [25,26,27] (for
review see [28,29]). Some of these discrepancies may be due to
distinct conditioning regimens, differences in the preparation, the
source and the dose of the transplanted stem cells and/or the fact
that the cohorts included patients with distinct hematological
malignancies that are based on different primary genetic lesions.
Despite some of the above correlations, it has not been shown
directly that NK cells control primary leukemic cells arising in vivo
and, if so, it is not clear which NK cell recognition strategy would
be most effective against leukemic cells. Finally it is not known
whether NK cells can target leukemia initiating stem cells and thus
whether NK cells have the potential to contribute to curing
leukemia.
Here we have addressed whether NK cells do have the
potential to control primary CML in vivo. To this end, we used a
well-established mouse model, in which bone marrow (BM)
precursor cells are transduced with the BCR-ABL1 oncogene.
Infected BM cells are transplanted into lethally irradiated
recipient mice, which develop a fatal CML disease [30,31]. This
disease model was combined with the classical model of BM graft
rejection mediated by host NK cells [32], which allowed us to
determine whether there was a difference in the efficacy of NK
cells against normal and leukemic cells. Our analyses reveal that
NK cell-mediated missing-self recognition, but none of the other
NK cell recognition strategies, significantly impacts the outgrowth
of CML cells in vivo. The NK cell mediated effect is based at least
in part on the targeting of leukemia initiating stem cells, which
suggests that NK cell recognition may contribute to cure CML
disease.
Results
Lack of NK cell recognition of MHC-I matched BCR-ABL1+
myeloid cells in vivo
To determine whether NK cells can protect against primary
BCR-ABL1+ cells in vivo, BM progenitor cells were infected with a
retrovirus encoding the BCR-ABL1 (p210) oncogene plus green
fluorescent protein (GFP) or with a control retrovirus expressing
only GFP. Transduced BM precursor cells (usually around 10%
GFP+) were transplanted into lethally irradiated recipient mice.
Polymorphisms in the CD45 molecule were utilized to discrim-
inate hematopoietic cells of donor (CD45.1) and recipient
(CD45.2) origin.
To address whether NK cells protect against MHC-I matched
BCR-ABL1+ cells, we estimated the abundance of GFP+ myeloid
cells (CD11b+) in recipient spleens 8 days (d8) after transplan-
tation (Fig. 1). B6 (H-2b)-derived BM precursors transduced with
the control virus yielded low numbers of GFP+ myeloid cells in
spleens of MHC-I matched B6 recipients (H-2b) (105 cells/spleen)
(Fig. 1A, B). Transduction with the BCR-ABL1 virus resulted in
significantly elevated numbers of GFP+ CD11b+ cells (56106
cells) (Fig. 1A, B), confirming that BCR-ABL1 expression
induces an expansion of myeloid cells. The depletion of
NK1.1+ cells prior to BM transplantation did not impact the
abundance of BCR-ABL1 expressing CD11b+ cells (Fig. 1B),
indicating that NK cells do not react to MHC-I-matched BCR-
ABL1 transformed cells.
NK cell mediated missing-self recognition reduces the
expansion of BCR-ABL1+ myeloid cells
We next addressed whether a partial MHC-I mismatch, which
results in NK cell mediated missing-self recognition, impacts the
expansion of BCR-ABL1 expressing cells. Control infected B6 BM
precursors yield myeloid cells in B6 hosts (105 cells) (Fig. 1B) but
not in B6 hosts expressing a H-2Dd transgene (H-2bDd)(,104 cells)
(Fig. 1D), illustrating NK cell mediated rejection of normal BM
grafts based on missing-self recognition [33,34]. The transplanta-
tion of BCR-ABL1 B6 BM progenitors into B6Dd hosts yielded a
large number of BCR-ABL1+ myeloid cells (.106 cells) when
NK1.1+ cells had been depleted (Fig. 1C, D). When NK cells
were present, the number of BCR-ABL1+-CD11b+ cells was
approximately 30 fold lower (Fig. 1C, D). Thus a partial MHC-I
mismatch significantly diminished the expansion of BCR-ABL1+
cells in vivo due to the presence of NK cells. This is likely mediated
by NK cells expressing inhibitory Ly49A+ and Ly49G2+
receptors, which are inhibited by H-2Dd but not H-2b molecules
[35].
We next tested whether complete MHC-I deficiency further
accentuated the protective effect. Indeed, the abundance of BCR-
ABL1+ myeloid cells that developed from b2m-deficient (b2m-ko,
MHC-Ilow) BM precursors was reduced 500 fold in the presence of
NK cells in B6 recipient mice (H-2b) (Fig. 1E, F). We conclude
that NK cell mediated missing-self recognition can efficiently
NK Cell Recognition of CML
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control myeloid expansion driven by the BCR-ABL1 oncogene in
vivo. The improved protective effect is likely due to a higher
number of mismatches between inhibitory receptors and MHC-I
ligands as observed for the NK cell mediated rejection of MHC-I-
different normal cells [36].
NK cell mediated ‘‘non-self’’ or ‘‘induced-self’’ recognition
fails to control BCR-ABL1+ cells
To address whether NK cell activation by non-self MHC-I
conferred a protective effect, we transplanted BCR-ABL1
expressing B6Dd BM precursors into B6 recipients. In this
donor/recipient combination, host NK cells partially reject
normal B6Dd BM allografts based on the H-2Dd-specific
Ly49D activation receptor [37]. However, NK cells in B6
recipients failed to impact the expansion of BCR-ABL1+ B6Dd
myeloid cells (Fig. 2A), indicating that NK cell mediated non-self
recognition is not effective against primary BCR-ABL1+ cells in
vivo.
There is considerable evidence that the engagement of the
NKG2D activation receptor by stress-induced ligands plays an
Figure 1. NK cell mediated missing-self recognition reduces the expansion of BCR-ABL1+ myeloid cells in vivo. BM cells from 5-FU
treated B6 mice (H-2b, CD45.1) were transduced with retroviral vectors encoding GFP (Control) or BCR-ABL1 plus GFP (BCR-ABL1) followed by
transplantation into lethally irradiated, MHC-I matched B6 (H-2b, CD45.2) mice (A, B) or MHC-I-different B6 Dd mice (H-2bDd, CD45.2) (C, D). In
addition, BM cells from 5-FU treated b2m-deficient (b2m-ko) mice (MHC-Ilow, CD45.2) were transduced with retroviral vectors encoding BCR-ABL1 plus
GFP followed by transplantation into B6 (H-2b, CD45.1) mice (E, F). Some recipient mice had been depleted of NK1.1+ cells by the injection of mAb
PK136 (anti-NK1.1). Histograms show the identification of donor-derived cells at day 8 after transplantation (upper panel). Donor-derived cells were
further analyzed for the presence of myeloid cells (CD11b+)(middle panel) and GFP expression in donor-derived myeloid cells (lower panel). Numbers
indicate the percentage of cells in the respective gate. Bar graphs show the mean absolute number (6SD) of donor-derived myeloid cells expressing
GFP (either control or BCR-ABL1) in recipient spleens at day 8 after transplantation. Donor-recipient mouse strain combinations were (B) B6 (H-2b,
CD45.1)-.B6 (H-2b, CD45.2) (MHC-I identical) and (D) B6 ((H-2b, CD45.1) into B6Dd (H-2bDd, CD45.2) (MHC-I different, partial missing-self) and (F) b2m-
ko (MHC-1low, CD45.2)2.B6 (H-2b, CD45.1) (MHC-I deficient, complete missing-self). The significance of the difference between indicated data sets is
depicted as *** p,0.001, ** p,0.01 and ns not significantly different p.0.05.
doi:10.1371/journal.pone.0027639.g001
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important role for the recognition of transformed cells by NK cells
[20]. While B6-background BCR-ABL1+ myeloid cells do not
express the NKG2D ligands Rae-1 (Fig. 2B) or Mult1 (not
shown), myeloid cells from certain mouse strains upregulate
Rae-1 following BM transplantation and this results in graft
rejection in specific recipient mouse strains [38]. Accordingly, we
used the MHC-I matched, unrelated strain combination of
BALB.B (H-2b)2.B6 (H-2b) to address whether induced-self
recognition can control BCR-ABL1+ cells. However, despite
significant expression of Rae-1 (but not MULT1 or H60) (Fig. 2B
and data not shown) we failed to observe a significant NK cell-
mediated effect on BALB.B BCR-ABL1+ myeloid cells (Fig. 2C).
Of note, though, we observed a significant NK cell-dependent
rejection of normal BALB.B myeloid cells (Fig. 2C), in
agreement with [38]. Thus, despite the expression of NKG2D
ligand, induced-self recognition of BCR-ABL1+ cells in vivo is
impaired.
NK cell mediated missing-self recognition can protect
from CML disease in vivo
Since NK cell mediated missing-self recognition impacted
myeloid expansion at d8 post transplantation, we next determined
whether recipient mice were protected from CML disease in vivo.
Since NK cell rejection of normal BM allografts is lethal between
d12 and d14 post transplantation we ensured the long-term
survival of host mice by co-transplanting MHC-I matched rescue
BM (Fig. 3A). Similar to the transplantation with a single type of
BM, such mixed BM grafts rapidly induced CML disease, which is
characterized by weight loss, increased numbers of peripheral-
blood cells (with a predominance of mature granulocytes),
splenomegaly and pulmonary hemorrhage, owing to granulocyte
infiltration into the lung (Fig. 3B) [31].
When BCR-ABL1+ BM was transplanted into MHC-I
matched recipients, the presence of NK cells did not improve
the survival of recipient mice, delay the onset of disease (Fig. 4A)
or alter any of the symptoms associated with CML disease (data
not shown). Corresponding observations were made when
BCR-ABL1+ B6 BM was transplanted into NK cell-sufficient
RAG-1-knock out mice (H-2b) and into NK cell-deficient RAG-1
common c chain double-knock-out mice (data not shown).
Thus, as expected, NK cells do not impact MHC-I matched
CML disease.
The transplantation of B6 BCR-ABL1+ BM into B6Dd hosts,
from which NK1.1+ cells had been depleted, resulted in CML
disease in 100% of recipient mice (mean onset day 11.061.3,
n = 14) (Fig. 4B). The presence of host NK cells significantly
delayed disease onset (mean onset day 13.763.1, n = 12)(p,0.01).
In addition, in the presence of NK cells, only 12 of 14 mice (86%)
succumbed to CML disease. The remaining recipients (2/12,
14%) remained disease free (.50d) (Fig. 4B). Thus a partial Ly49
ligand mismatch reduced CML disease in vivo.
In contrast to the early time point after transplantation (d8)
(Fig. 1C, D), animals with CML disease had comparable
numbers of BCR-ABL1+ myeloid cells, irrespective of whether
NK cells were deleted or not (Fig. 5A). The eventual failure to
prevent disease progression was not due to a loss of NK cells. On
the contrary, NK cells were actually slightly more abundant at
later time points (Fig. 5B). Thus the initial control of leukemic
cells is incomplete and BCR-ABL1+ myeloid cells eventually
escaped NK cell-mediated missing-self recognition.
Finally we tested whether complete MHC-I mismatch provided
an improved protection against CML disease. In the absence of
NK cells, the majority of B6 recipients receiving b2m-ko BCR-
ABL1+ BM developed disease symptoms (70%, 7/10) (Fig. 4C).
In contrast, when NK cells were present most recipients of b2m-ko
BCR-ABL1+ BM remained disease free (89%, 8/9) for .45d
(Fig. 4C). Interestingly, the only recipient that developed disease,
had symptoms characteristic of B-ALL (B cell acute lymphocytic
leukemia) rather than CML. B-ALL is characterized by a
moderate splenomegaly and enlarged lymph nodes due to an
expansion of B220+ B cells and such mice do not have the
extensive infiltration of the lung and liver characteristic of CML
Figure 2. NK cell mediated non-self or induced-self recognition
does not impact the expansion of BCR-ABL1+ cells. (A) The bar
graph shows the mean absolute number (6SD) of B6 Dd (H-2bDd,
CD45.1)-derived myeloid cells expressing BCR-ABL1 (GFP) in B6 (H-2b,
CD45.2) recipients at day 8 after transplantation (MHC-I different, non-
self recognition). (B) The expression of Rae-1 NKG2D ligands was
determined on B6 (left) or BALB.B (right)-derived myeloid cells (CD11b+)
expressing BCR-ABL1 on day 8 after transplantation into B6 mice (gray
fill). Open histograms depict background staining on BM-derived
CD11b+ cells of normal B6 mice. (C) The bar graph shows the mean
absolute number (6SD) of BABL.B (H-2b, CD45.2)-derived myeloid cells
expressing GFP (either control or BCR-ABL1) in B6 (H-2b, CD45.1)
recipients at day 8 after transplantation (MHC-I matched, unrelated,
induced-self recognition).
doi:10.1371/journal.pone.0027639.g002
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(data not shown). In the absence of NK cells, some B6 recipients of
BCR-ABL1+ b2m-ko BM also developed B-ALL (2/7 mice that
were diseased). However most recipients developed CML (5/7).
These experiments formally show that following BM transplanta-
tion, NK cell mediated missing-self recognition can protect from
CML disease.
NK cell recognition of BCR-ABL1+ leukemia initiating cells
Finally we addressed whether NK cells exerted their
protective effect by targeting mature BCR-ABL1+ myeloid
cells, immature myeloid precursors or the small population of
leukemia initiating cells, which propagate CML disease [39]. As
mentioned above, NK cell mediated missing-self recognition
strongly reduced the abundance of mature BCR-ABL1+
myeloid cells (Fig. 1). Moreover, myeloid/erythroid progenitor
cells (Lin- Kit+ Sca-1- (LKS-)) GFP+ were also strongly reduced
(Fig. 6A, B, D), suggesting that NK cells efficiently target
immature myeloid progenitors. Finally, the abundance of
leukemia initiating cells, which are present in the haematopoi-
etic stem cell compartment (Lin- Sca-1+ c-kit+) (LSK)
expressing BCR-ABL1 [40], was significantly reduced based
on a partial MHC-I deficiency of the graft relative to the host
(Fig. 6A, C). Leukemia initiating cells were essentially absent
when the graft lacked MHC-I molecules (Fig. 6E). These data
show that NK cell-mediated missing-self recognition can target
leukemia initiating cancer stem cells and that this correlates with
protection from CML disease.
Discussion
A potential role of NK cells to prevent leukemia relapse has
been suggested based on the retrospective analysis of data from
patients receiving unrelated HLA matched or partially HLA
mismatched bone marrow transplantation. However, direct
evidence that NK cells can prevent leukemia relapse is lacking
and it has remained unclear what NK cell recognition events
might be effective. Here we provide direct evidence that NK cells
can be effective against primary CML in vivo. Unexpectedly, a
protective effect was only observed for NK cell mediated missing-
self recognition whereby an increased MHC-I receptor-ligand
mismatch improved the protective effect in vivo. In contrast, the
positive recognition of allogeneic MHC-I exerted no measurable
effect on the abundance of BCR-ABL1-expressing myeloid cells
in vivo. Further, it was possible that lethal irradiation/BM
transplantation produced a cytokine milieu that reversed the
reduced responsiveness of activation receptors on non-educated
NK cells (i.e. Ly49A+ and Ly49G2+ NK cells in H-2b mice),
which are not inhibited by the MHC-I of the tumor. However,
the absence of an effect of NK cells upon MHC-I matched
transplantation provides circumstantial evidence that uneducated
NK cells do not become reactive against BCR-ABL1+ cells.
Finally, the recognition of stress-induced ligands by NKG2D also
failed to mediate a significant protective effect against leukemia,
even in a situation where the respective ligand(s) are expressed.
Since normal BM cells that express NKG2D ligand are rejected,
the data raise the possibility that BCR-ABL1 expression impairs
Figure 3. Schematic representation of CML protection assays. (A) NK cell rejection of normal BM allografts is lethal between d12 and d14
post transplantation. To ensure the survival of host mice beyond this time point, lethally irradiated recipient mice were transplanted with mixtures of
MHC-I matched rescue BM plus MHC-I-different BCR-ABL1 transduced BM. (B) Mixed BM grafts rapidly induces CML disease, which is characterized by
pulmonary hemorrhage, splenomegaly and increased numbers of mature granulocytes in peripheral blood.
doi:10.1371/journal.pone.0027639.g003
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the recognition of cells expressing NKG2D ligand. This defect
was not based on a down-regulation or loss of the NKG2D
receptor on NK cells (data not shown). Collectively, we have been
unable to identify NK cell recognition events that allow the
selective detection of BCR-ABL1+ as compared to normal host
cells. Rather this study has identified NK cell recognition events
that are impaired due to the expression of BCR-ABL1. Missing-
self recognition was the only NK cell recognition strategy, which
was not impaired and which significantly impacted the course of
CML disease.
The NK cell activation receptors (and their ligands) mediating
missing-self recognition remain incompletely defined. It is clear,
however, that NK cells are activated by multiple receptors
specific for constitutively expressed ligands on healthy host cells.
The predominant reactivity of NK cells for cells of haemato-
poietic origin is explained in part by the expression of SLAM
family receptors/ligands by haematopoietic cells [41]. Such
restricted expression of ligands may also explain the observation
that NK cells do not mediate GvHD [42]. The identification of
all the activating receptors and their ligands will be required to
explain why missing-self recognition is particularly effective
against CML and whether the recognition of CML is dependent
on the same or partially distinct activation receptors. Moreover,
this knowledge will be essential to understand how CML
eventually escapes NK cell mediated missing-self recognition. In
addition to specific receptor-ligand interactions, it is also
possible that the particular cytokine milieu generated in the
course of conditioning and BM transplantation favors missing-
self reactivity.
Here we have aimed at determining the potential of NK cells
to protect from CML following BM transplantation. The
advantage of our set-up is that the efficacy of NK cells against
BCR-ABL1+ cells can be compared to that against normal cells,
which is well established based on classical BM graft rejection
experiments. Indeed, as detailed above, we did identify significant
differences between the control of normal and BCR-ABL1+ BM
progenitors. It is clear, however, that GvL is mediated by donor-
derived and not by host-derived NK cells. Thus future studies will
verify whether missing-self recognition by donor-derived NK cells
is equally effective. While missing-self recognition has the
potential to protect from CML disease, the efficacy of host NK
cells against partially mismatched CML was limited. Despite a
delay in disease onset, the majority of recipient mice (12/14;
86%) eventually succumbed to CML disease. While NK cells
largely controlled BCR-ABL1+ myeloid cells at an early time-
point after transplantation (day 8), in diseased animals the
abundance of CML cells and their precursors was comparable,
independent of the presence of NK cells. The eventual lack of
control was not due to a complete loss host NK cells. On the
contrary, host NK cells were slightly more abundant in the spleen
of diseased mice. In agreement with these data, normal allogeneic
BM induces the expansion of adoptively transferred NK cells
[43]. Irrespective of this, BCR-ABL1+ cells eventually escape NK
cell mediated control. The limited efficacy of NK cells may be
Figure 4. NK cell-mediated missing-self recognition can protect
from BCR-ABL1 induced CML disease. A Survival graph of B6
recipients (H-2b) transplanted with a mixture of BCR-ABL1 transduced
B6 BM cells (H-2b) and non-transduced B6 rescue BM (H-2b). Some
recipient mice had been depleted of NK1.1+ cells by the injection of
mAb PK136 (anti-NK1.1). These data are derived from a single
experiment. B Survival graph of B6Dd recipients (H-2bDd) transplanted
with mixtures of control transduced B6 BM (H-2b) and non-transduced
B6Dd rescue BM (H-2bDd). All recipient mice survived independent of
the presence or absence of NK1.1+ cells (6anti-NK1.1). Survival of B6Dd
recipients (H-2bDd) transplanted with mixtures of BCR-ABL1 transduced
B6 BM (H-2b) and non-transduced B6Dd rescue BM (H-2bDd). In the
presence of NK cells, the survival of recipients is significantly improved
(p,0.01). The data have been compiled from three independent
experiments. C Survival graph of B6 recipients (H-2b) transplanted with
mixtures of BCR-ABL1 transduced b2m-ko (MHC-Ilow) BM and non-
transduced B6 rescue BM (H-2b). In the presence of NK cells, the survival
of recipients is significantly improved (p,0.01). The data have been
compiled from two independent experiments.
doi:10.1371/journal.pone.0027639.g004
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explained by irradiation damage to host NK cells. Indeed, we
have noted that lethal and even sub-lethal irradiation significantly
reduces the abundance of splenic NK cells (5 fold). Moreover,
within the first few days after transplantation residual host NK
cells do not proliferate [44] (and our unpublished data). As
donor-derived or adoptively transferred NK cells should not be
damaged, it will be of interest to see whether these NK cell
populations are more effective against CML. On the other hand,
recent data suggest that the systemic exposure of mature NK cells
to a large number of MHC-I-deficient normal cells profoundly
reduces NK cell function [45]. Induction of NK cell hypo-
responsiveness seems to be the outcome when mature NK cells
are persistently stimulated under non-inflammatory conditions.
Indeed, when NK cells are stimulated in the context of an
inflammatory environment their function can stably improve
[46,47]. If so, approaches to keep stimulated NK cells functional
in a non-inflammatory environment may be needed to obtain
protective effect against leukemia. The mouse models used here
should be useful to address these issues.
Significantly we provide evidence that NK cells can impact the
course of CML disease by targeting leukemia initiating stem cells
that are refractory to the control by BCR-ABL1 tyrosine kinase
inhibitors. These data suggest that NK cell recognition has the
potential to cure CML. Finally, our findings validate approaches
to treat leukemia using mAb-based blockade of self-specific
inhibitory MHC-I receptors [48,49] and they may influence the
selection of optimal donor/recipient combinations for stem cell
transplantation to treat leukemia.
Materials and Methods
Mice
C57BL6 (B6) mice (H-2b; CD45.2) were purchased from Harlan
Olac (The Netherlands), CD45.1 congenic B6 mice (H-2b;
CD45.1). BALB.B (H-2b; CD45.2) and b2m-deficient B6 mice
(MHC-Ilow; CD45.2) were originally purchased from The Jackson
lab (Bar Harbor, ME) and maintained at the LICR. H-2Dd
transgenic mice, backcrossed .10 generation to B6 (B6 Dd) (H-
2bDd; CD45.2) have been described before [34]. Animal
experimentation followed protocols reviewed and approved by
the Service Ve´te´rinaire du Canton de Vaud (authorization
number 1124).
Retroviral infection and bone marrow transplantation
Retroviral infection and BM transplantation was performed
essentially as described in [31]. Briefly, plasmids containing
MSCV IRES GFP and MSCV BCR-ABL1 (p210) IRES GFP
were transiently transfected into 293T cells for high titer virus
production using standard procedures. BM donor mice were
injected with 5-Fluorouracil (5-FU) (0.15 mg/ml) and BM cells
were harvested 4 days later. BM cells were cultured in DMEM
(plus 10% FCS, 50 mM 2-ME, 50 U/ml penicillin/50 mg/ml
streptomycin, 10 mM HEPES) supplemented with IL-3 (10 ng/
ml), IL-6 (10 ng/ml) and SCF (50 ng/ml) for 48 h and infected
Figure 5. BCR-ABL1+ myeloid cells escape NK cell mediated
control. (A) The bar graph shows the mean number (6SD) of donor-
derived GFP+ (control or BCR-ABL1) myeloid cells in the spleen of
recipient mice at d8 after transplantation (left) and when CML disease
had developed (right). Some recipient mice had been depleted of
NK1.1+ cells by the injection of mAb PK136 (anti-NK1.1). (B) Mean
number (6SD) of host-derived NK cells in the spleen of recipient mice
at d8 after transplantation and when CML disease had developed
(right). Significant differences between groups is indicated as * p,0.05,
** p,0.01 and *** p,0.001; (ns) not significantly different p.0.05.
doi:10.1371/journal.pone.0027639.g005
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with retrovirus in the presence of polybrene (8 mg/ml). After
24 h, 105 cells (usually around 10% GFP+) were injected i.v. into
lethally irradiated recipient mice (2 doses of 480rad 4 h apart
from a 137Cs source). One day prior to irradiation, some recipient
mice were injected i.p. with 200 mg of mAb PK136 (anti-NK1.1)
to deplete NK1.1+ cells. Recipient mice were sacrificed at day 8
after transplantation and analyzed by flow cytometry (see below).
Alternatively, for leukemia induction experiments, irradiated
recipient mice were transplanted with a mixture of infected BM
and non-infected (MHC-I-matched) rescue BM (105 each), both
derived from 5-FU treated donors. Recipient mice were
monitored daily for weight loss and failure to thrive. Pre-morbid
animals were sacrificed and relevant tissues were harvested and
analyzed visually and by flow cytometry (see below). For
continuous depletion of NK1.1+ cells, recipient mice were
injected i.p. with 200 mg of mAb PK136 (anti-NK1.1) one day
prior to irradiation and mAb injection was repeated every 2
weeks.
Flow cytometry
Spleen and BM cells were incubated with 2.4G2 (anti-CD16/
32) hybridoma supernatant (to block Fc receptors) before
staining for multi-color flow cytometry. The following mAbs
were used: CD3e (17A2), CD4 (GK1.5), CD8 (53.6.7), CD11b
(Mac1)(M1/70), CD41 (MWReg30), CD45R (B220) (RA3-6B2),
CD45.1 (A20.1), CD45.2 (104), CD117 (ACK2), CD127
(A7R34), CD135 (FLT3R)(A2F10.1), CD161 (NK1.1) (PK136),
GR1 (RB6-8C5), TCRb (H57), TCRcd (GL3) and Ter119, Rae-
1 (186107: R&D), Mult-1 (5D10: eBiosciences). Abs were
conjugated with appropriate fluorochromes at the LICR or
purchased from BD PharMingen (San Diego, CA) or eBioscience
(San Diego, CA).
A cocktail of FITC-conjugated mAbs to TCRb, TCRcd, CD3e,
CD4, CD8, Mac-1, B220, NK1.1, Ter119 and GR1 was used to
gate out cells expressing markers of mature lineage-cells (Lin) cells.
Samples were run on a FACSCanto flow cytometer and analyzed
with Cell Quest or FACS Diva software (Becton Dickinson, San
Jose, CA).
Statistical analysis
A two-tailed student’s t-test was used to determine significant
differences between data sets and a Gehan-Wilcoxon test was used
to compare survival curves. Data sets were considered significantly
different when p,0.05.
Figure 6. NK cell mediated missing-self recognition reduces the
abundance of BCR-ABL1+ leukemia initiating cells. (A) B6 BM
cells (H-2b) were transduced with a retrovirus expressing GFP (Control)
or BCR-ABL1 plus GFP (BCR-ABL1) and transplanted into lethally
irradiated B6Dd recipient mice (H-2bDd). Recipient spleens were
analyzed by flow cytometry at d8 post transplantation. Donor-derived
cells lacking markers of mature lineage cells (Lin-) were analyzed for the
expression of c-kit and Sca-1 (top row). Histograms (gray filled) depict
GFP expression (Control or BCR-ABL1) in gated Lin- c-kit+ sca-1- (LKS-)
cells (myeloid/erythroid progenitors) (middle row) and in Lin- c-kit+ sca-
1+ (LSK) cells (haematopoietic stem cell compartment) (bottom row).
Open histograms depict background staining using BM precursor cells
from normal B6 mice. Numbers indicate the percentage of cells in the
respective gate. Some recipient mice had been depleted of NK1.1+ cells
(anti-NK1.1). The bar graphs show the mean absolute number (6SD) of
donor-derived GFP+ (Control or BCR-ABL1) LKS- cells (myeloid/erythroid
progenitors) (B) and LSK cells (haematopoietic stem cell compartment)
(C) at d8 after transplantation. (D, E) The bar graphs show the mean
absolute number (6SD) of b2m-ko-derived GFP+ (Control or BCR-ABL1)
LKS- cells (D) and LSK cells (E) at d8 after transplantation into B6 (H-2b)
recipients. Significant differences between groups are indicated as
* p,0.05, ** p,0.01 and *** p,0.001; (ns) not significantly different
p.0.05.
doi:10.1371/journal.pone.0027639.g006
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